Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Bavarian Nordic board backs higher bid amid shareholder holdout
16 Oct 2025, 05:28BAVA.CONASDAQ Copenhagen

Bavarian Nordic's board of directors on Thursday reiterated its recommendation for shareholders to accept a takeover offer from a private equity consortium led by Nordic Capital and Permira.

Private equity raises Bavarian Nordic bid, faces shareholder test
15 Oct 2025, 15:59BAVA.CONASDAQ Copenhagen

A private equity consortium led by Nordic Capital and Permira has raised its takeover bid for Danish vaccine maker Bavarian Nordic to 250 Danish Krone per share from 233 Danish Krone.

Nordic Capital, Permira clear final hurdle for Bavarian Nordic takeover
9 Oct 2025, 12:24BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has received the final regulatory approval needed for its proposed takeover of Danish vaccine maker Bavarian Nordic.

Bavarian Nordic's mpox vaccine shows strong results in children
7 Oct 2025, 14:59BAVA.CONASDAQ Copenhagen

Bavarian Nordic said Tuesday its mpox and smallpox vaccine produced a strong immune response and was well-tolerated in children aged 2 to 11 in a clinical study.

Bavarian Nordic posts strong results ahead of PE buyout
22 Aug 2025, 05:38BAVA.CONASDAQ Copenhagen

Danish vaccine maker Bavarian Nordic on Friday reported a 33% rise in first-half revenue, posting strong results as it prepares for a takeover by a private equity consortium.

Bavarian Nordic agrees to DKK 19 billion takeover offer
6 Aug 2025, 20:30BAVA.CONASDAQ Copenhagen

A consortium led by private equity firms Nordic Capital and Permira has agreed to acquire Danish vaccine maker Bavarian Nordic in an all-cash deal valuing the company at approximately 19 billion Danish Krone.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Bavarian Nordic issues warrants22 Aug 2013
Bavarian Nordic Receives European Marketing Authorization for IMVANEX Smallpox Vaccine7 Aug 2013
Bavarian Nordic's IMVANEX® Smallpox Vaccine Receives Positive Opinion from European Regulatory Authorities31 May 2013
Bavarian Nordic's CV-301 Cancer Immunotherapy Candidate Shows Promise in Colorectal Cancer29 May 2013
Bavarian Nordic Establishes a Sponsored Level 1 ADR Program in the US29 May 2013
Bavarian Nordic - Interim Financial Report for the Period 1 January to 31 March 201316 May 2013
Bavarian Nordic A/S - Articles of Association2 May 2013
Bavarian Nordic A/S - Major Shareholder Announcement24 Apr 2013
Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 17 April 201317 Apr 2013
Bavarian Nordic Receives Contract Valued up to USD 228 Million from the U.S. Government Securing Continued Production and Deliveries of IMVAMUNE® Smallpox Vaccine16 Apr 2013
Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 Trial8 Apr 2013
Bavarian Nordic A/S - Notice Convening Ordinary General Meeting19 Mar 2013
  • Previous
  • 1
  • More pages
  • 43
Search
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
  • 3
  • Next
  • 44
  • 45
  • More pages
  • 78
  • Next
  • Filings
    927